| Package | us.nlm.vsac |
| Type | ValueSet |
| Id | 2.16.840.1.113762.1.4.1196.4470 |
| FHIR Version | R4 |
| Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1196.4470/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4470 |
| Version | 20240515 |
| Status | active |
| Date | 2024-05-15T01:01:25-04:00 |
| Name | EmtricitabineOralForHIVPrEP |
| Title | Emtricitabine oral for HIV PrEP |
| Realm | us |
| Authority | hl7 |
| Description | Under Cooperative Agreement number 6-NU38OT000316, funded by the CDC Division of Sexually Transmitted Disease Prevention and the Division of HIV Prevention, the Public Health Informatics Institute coordinated a project to test the feasibility, usability and acceptance of a CDS solution aimed at increasing adherence to public health guidelines for treating gonorrhea, encouraging human immunodeficiency virus screening and raising awareness of pre-exposure prophylaxis prescriptions in clinical settings. See https://phii.org/sti-connect-cds/ for full information. This value set was created to support that work and could be used to inform the development of a similar solution in a clinical environment. It is important to note that the CDS solution incorporated portions of public health guidelines for GC treatment, HIV screening and PrEP education and does not reflect a full implementation of the guidelines. |
| Purpose | (Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: Only emtricitabine with tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF)),(Exclusion Criteria: ) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
No narrative content found in resource
FHIR